Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motexafin Gadolinium in Metastatic Renal Cell Carcinoma
NCT00134186Phase 2Completed
- Sponsor
- Pharmacyclics
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of motexafin gadolinium in renal cell carcinoma (RCC), sponsored by Pharmacyclics. Status: completed.
02
Drugs
motexafin gadolinium
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00134186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00134186.